Archive | Press Releases

RSS feed for this section

Daxor Corporation Announces Share Buyback Program

New York, NY November 1, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced today that an updated buyback program has been unanimously approved by Daxor’s Board of Directors. The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of […]

Daxor Corporation Holds Annual Meeting Provides Business Growth Update and Strategic Plan

New York, NY June 29, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, (NYSE:DXR) held its annual meeting on June 27th in New York City, where it briefed investors on its progress in growing its medical technology operating company supplying the Daxor BVA-100 blood volume analysis device. […]

Daxor Corporation Announces Reinstatement of Compliance with the New York Stock Exchange (NYSE MKT LLC)

New York, NY June 26, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, received a letter from the New York Stock Exchange informing Michael Feldschuh, President and Chief Executive Officer of Daxor Corporation, that the Company is “Back in compliance with the NYSE MKT LLC continued listing […]

Daxor Corporation Announces Delay in Filing of Form N-CSR for December 31, 2016, and the Uniformed Services University of Health Sciences has been awarded a grant to study hemodilution utilizing Daxor’s BVA-100 device

NEW YORK, NY–(Marketwired – Apr 10, 2017) – On April 10, 2017, Daxor Corporation (NYSE MKT: DXR) received a letter from the NYSE MKT LLC (“the Exchange”) noting that it is not in compliance with the listing standards pertaining to the timing of SEC filings as set forth in Sections 134 and 1101 of the […]

SCCM17 Randomized Controlled Trial Analysis: Individualized Volume Management Guided by Direct Blood Volume Analysis (BVA) Sharply Lowers Early ICU Mortality vs Pulmonary Artery Catheter Alone

New York, NY January 30, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces a new randomized controlled trial analysis presented in at the Society of Critical Care meeting this month confirming a markedly lower ICU mortality rate with fluid and red blood cell management individualized according […]

Daxor Corporation Announces Death of Founder, Chief Medical Officer, and Developer of Blood Volume Analysis and Inventor the Daxor BVA-100 Device, Dr. Joseph Feldschuh

New York, NY February 1, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, sadly announced today the death of the Company’s founder and its first President and Chief Executive Officer, Dr. Joseph Feldschuh. Dr Feldschuh, who was working on a part-time basis and responding well treatment for […]

Daxor Corporation Announces Dividend, Patent Approval, Title Change

New York, NY, November 18, 2016 – Daxor Corporation, an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend for 2016. The Board of Directors has unanimously approved an annual dividend payment of $0.03 per share. This dividend will be paid on Thursday, December 29, 2016 to Daxor shareholders of […]

Two New Studies from the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Society of America 2016 Highlight Unique Ability of BVA to Identify High Risk at Discharge in Hospitalized Heart Failure Patients

New York, NY September 29, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces two new studies presented at the Heart Failure Society of America meeting this month highlighting risks for hospitalized heart failure patients detectable by direct blood volume measurement (Daxor BVA-100). Michael Feldschuh, President and […]

Daxor Corporation Announces Filing of Form N-CSR for June 30, 2016

New York, NY September 15, 2016 – Marketwired – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed its Form N-CSR on Tuesday, August 30, 2016 disclosing its schedule of portfolio holdings as of June 30, 2016. Copies of the form will be mailed to the Company’s shareholders and […]

Daxor Corporation Announces Hiring of Chief Financial Officer

New York, NY June 17, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces the hiring of Eric P. Coleman as its new Chief Financial Officer effective June 6, 2016, reporting directly to Michael Feldschuh, Acting President & CEO of Daxor Corporation. “Mr. Coleman will be responsible […]